An Open-Label Multicenter Study of Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer Patients Previously Treated With Sipuleucel-T on Dendreon Study P-11 (NCT00779402)

Trial Profile

An Open-Label Multicenter Study of Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer Patients Previously Treated With Sipuleucel-T on Dendreon Study P-11 (NCT00779402)

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Feb 2017

At a glance

  • Drugs Sipuleucel-T (Primary)
  • Indications Prostate cancer
  • Focus Pharmacodynamics
  • Sponsors Dendreon Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
    • 06 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top